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Background: The aim of this study was to evaluate whether hepatic resections of ovarian cancer liver metastases
provide a benefit in terms of survival as part of primary, secondary, tertiary, and even quaternary cytoreductive
surgery.
Methods: Data of patients submitted to surgery for ovarian cancer liver metastases at Fundeni Clinical Institute
between January 2002 and April 2014 were retrospectively reviewed. Liver lesions were classified according to their
origin in parenchymal and peritoneal lesions.
Results: A total of 31 patients were identified: 11 of them underwent liver resection as part of primary
cytoreduction, 15 at secondary cytoreduction, 3 at tertiary cytoreduction, and 2 at the time of quaternary
cytoreduction. The survival of patients with primary cytoreduction including liver resection was significantly higher
compared with that of patients with secondary cytoreductive surgery including liver resection (15.63 versus
6.63 months, log-rank p = 0.057, 90 % CI). The median survival of patients with hepatectomy for liver metastases
from peritoneal seeding was higher than that of patients with hepatectomy for liver metastases from
hematogenous origin (16.08 versus 12.66 months, log-rank p = 0.523).
Conclusions: Hepatectomy in ovarian cancer liver metastases is a safe and effective procedure; however, a benefit
in terms of survival in favor of peritoneal seeding has been systematically observed.Background
Ovarian cancer is the leading cause of death from gyne-
cologic malignancies, with an estimated incidence of
22,240 new patients and 14,030 deaths due to the
disease in the United States in 2013. As no effective
screening tests exist and symptoms are discrete, most
patients are diagnosed in advanced stages (III and IV)
[1]. The mainstay of treatment is surgery, followed by
platinum-based chemotherapy. As far as surgery is con-
cerned, the idea of maximal cytoreduction is a clearly
established concept with intense correlation between the
amount of remaining tumoral tissue and survival [2, 3].
However, the majority of patients will recur at some
point [4], and evidence is becoming available regarding* Correspondence: nicolaebacalbasa@gmail.com
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even tertiary setting [5]. Also, the benefit of extensive
upper abdominal procedures in the attempt to achieve
complete cytoreduction is advocated [6]. Since up to
50 % of patients who die of ovarian cancer have liver
involvement at autopsy [7], and some are up front di-
agnosed with liver metastases, one could question a
possible benefit for liver resection especially for a dis-
ease in which the mainstay of treatment is maximal
cytoreductive surgery. However, even though literature
regarding the benefit of liver resection for non-colorectal
non-neuroendocrine liver metastasis is increasingly being
published, there are few studies regarding liver metastases
from gynecologic primaries [7–18].
Methods
Data of patients who underwent surgery for advanced and
recurrent ovarian cancer at Fundeni Clinical Hospitals article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Table 1 Characteristics of patients undergoing liver resection as
part of primary cytoreductive surgery
Characteristics No. of patients (n = 11)
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reviewed. Written informed consent was obtained from
the patients for the publication of these data. Patients sub-
mitted to liver resection for ovarian cancer liver metastases
at the moment of primary, secondary, tertiary, and quater-
nary cytoreduction were considered eligible for the study.
A total of 31 patients were identified: 11 of them under-
went liver resection as part of primary cytoreduction, 15 of
secondary cytoreduction, 3 of tertiary cytoreduction, and 2
at the moment of quaternary cytoreduction. Liver lesions
were classified according to their origin in parenchymal
and peritoneal lesions. Parenchymal lesions were defined
as metastases with hematogenous origin, entirely devel-
oped intra-parenchymatously and entirely surrounded by
liver parenchyma. Metastases originating from peritoneal
seeding were considered those lesions developed on the
liver surface with parenchymal invasion of at least 2 cm.
Preoperative, intraoperative, and postoperative data
were collected retrospectively. The information
included age at initial diagnosis; stage (Federation
of Gynecology and Obstetrics (FIGO) systems); differen-
tiation grade (well (G1), moderately (G2), or poorly (G3)
differentiated carcinomas); histopathological type of the
primary tumor; neoadjuvant chemotherapy; associated
resections at the moment of each cytoreductive surgery;
disease-free survival; number, maximum dimensions,
type (peritoneal versus hematogenous), and intrahepatic
distribution of the liver metastases; postoperative com-
plications according to Dindo-Clavien classification; and
overall survival estimated from the moment of perform-
ing hepatic surgery. Liver resection was considered
major if more than two liver segments were resected,
while minor hepatectomies referred to less extended re-
sections. Type of resection was defined as follows:
R0—no remnant tumoral tissue, R1—tumoral tissue be-
tween 0 and 1 cm, and R2—tumoral tissue >2 cm. Dates
of death were obtained from the National Register of
Population. The differences between different subgroups
were analyzed by the log-rank test and considered signifi-
cant if p < 0.05. Kaplan-Meyer survival curves were also
used. Statistics and graphics were performed using the
SPSS software version 17.0 (SPSS, Chicago, IL, USA).
Results
From January 2002 to April 2014, 31 patients with liver re-
section for ovarian cancer liver metastases were evaluated.
Primary cytoreduction for ovarian cancer including liver
resection
At the moment of primary cytoreduction, 11 patients
with mean age of 54 years (range, 24–70) old underwent
liver resections for hepatic metastases. Two patients re-
ceived neoadjuvant therapy. The main characteristics at
the moment of primary cytoreduction are shown in
Table 1. All 11 patients were submitted to surgery withradical intent. Table 2 shows the main perioperative
characteristics of the patients included with stage IIIC–
IV of disease. No operative 30-day postoperative deaths
occurred, and the morbidity rate related to primary
cytoreduction was 25 %. Severe postoperative complica-
tions (> grade III Dindo-Clavien) were present in two
patients (25 %) with stage IV of disease.
Median survival of this group of patients was
15.63 months (range, 1–139), 34.33 months (range, 8–
139) in patients with peritoneal liver metastases, and
15.63 months (range, 7–128) for patients with
hematogenous liver metastases origin (log-rank p = 0.702).
Secondary cytoreduction for ovarian cancer including
liver resection
At the moment of secondary cytoreduction, 15 patients
underwent liver resections. Disease-free survival (DFS)
after primary cytoreductive surgery was 30 months
(range, 7–88 months). The mean age at the moment of
liver resection was 53 years (range, 33–71). The main
characteristics of patients diagnosed with liver metasta-
ses at the moment of secondary cytoreduction are shown
in Table 3. Six patients presented liver metastases with
peritoneal origin, while the other nine patients were di-
agnosed with parenchymal lesions. The mean of the
maximum diameter of liver lesions was 3.3 cm (range,
2–10 cm). An R0 resection was attempted in all patients;
however, this was possible in 80 % of patients (12 of 15
patients). In two patients, an R2 resection was performed.
The intraoperative findings and types of resection are
summarized in Table 4. No postoperative death was
Table 2 Intraoperative findings, types of resection, and early
postoperative outcomes of patients undergoing liver resection







Stage IIIC Stage IV
Number of liver metastasis
- Single 2 7
- Multiple – 1





- Peritoneal 2 1
- Parenchymatous – 7
Distribution
- Unilobular 2 7
- Bilobular – 1
Type of resection
- R0 2 6
- R1 – –
- R2 – 1
- Palliation/biopsy – 1
Type of liver resection
- Minor hepatectomies 2 5
- Major hepatectomies (>2 segments) – 1
- Radiofrequency ablation – 1
Associated visceral resections
- Total hysterectomy with bilateral
adnexectomy
2 6
- Omentectomy 1 8
- peritonectomy 1 8
- Splenectomy – 1
- Bowel resection 1 3
- Distal pancreatectomy – 1
- Subtotal gastrectomy – 1
- Diaphragmatic resection 1 2
Table 3 The main preoperative characteristics of patients
undergoing liver resections as part of secondary cytoreductive
surgery
Characteristics No. of patients
Mean age at primary cytoreduction 51 years (32–68)
















DFS (months) 30 (7–88)
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operative complications. Only two patients (13 %) devel-
oped complications related to liver resection—biliary
fistula in one patient and hepatic abscess as well in one
patient. The other complications were rather associated
to the other synchronous surgical procedures, such as
resection of pelvic recurrences involving bowel resec-
tion. Median survival for patients with liver resection at
secondary cytoreduction for ovarian cancer was
6.16 months (range, 1–66) for patients with hematogenous
liver metastases (n = 9) and 14.51 months (range, 4–138)for patients with liver metastases of peritoneal origin
(n = 6) (log-rank p = 0.197).
Tertiary cytoreduction for ovarian cancer including liver
resection
At the moment of tertiary cytoreduction, three patients
were diagnosed with liver metastases. The mean age at the
moment of tertiary cytoreduction was 60 years (range,
54–72), and the initial FIGO stages were I, II, and IIIC, re-
spectively. The mean interval from the moment of initial
diagnosis was 54 months (range, 14–91 months). Two of
the three patients were diagnosed with unique hepatic me-
tastases, both patients originating from initially early stage
tumors, while the third patient, initially classified as IIIC,
presented disseminated liver metastases with peritoneal
origin. In the other two patients, the hematogenous route
was incriminated. One patient was submitted to a major
hepatic resection involving more than two segments for a
4-cm parenchymal lesion, while the other two were sub-
mitted to minor hepatectomies. The mean diameter of the
tumors was 2.3 cm (range, 1–4 cm) while the histology
revealed serous histology in all patients. One of the
three patients experienced early re-operation for peri-
tonitis due to urinary fistula after segmental ureteral re-
section and reimplantation; death occurred 6 days after
re-operation. The other two patients experienced a sur-
vival of 63 and 70 months, the last one being still alive
by the end of the study.
Table 4 Intraoperative findings and types of resection of
patients undergoing liver resections as part of secondary
cytoreductive surgery
Number of liver metastasis
- Single 7
- Multiple 8












Type of liver resection
- Minor hepatectomies 14




- Bowel resection 4
- Cystectomy 3
- Subtotal gastrectomy 1
- Diaphragmatic resection 3
Fig. 1 Survival following liver resection as part of primary cytoreductive su
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liver resection
Two patients were submitted to liver resections during
quaternary cytoreduction. Both patients were initially diag-
nosed with stage IIC ovarian cancer and experienced liver
recurrence 3 years after initial surgery. The ages at the mo-
ment of liver resection were 39 and 48 years, respectively.
Liver resections were performed at 40 and 33 months re-
spectively from ovarian cancer diagnosis. One patient was
diagnosed with hepatic recurrence with peritoneal origin
while the second one was diagnosed with both parenchy-
mal and peritoneal lesions. The liver lesion diameters were
2 and 4 cm, respectively; both patients were submitted to
atypical hepatectomies; an R0 resection was feasible in a
single patient, while in the other, an R1 resection was per-
formed. Histopathological findings revealed a serous sub-
type in both patients. None of the patients experienced
postoperative complications. The postoperative survival
was 16 and 20 months after liver resection, both patients
being dead of disease by the end of the study.
Analysis of survival following hepatic resection based on
the type of cytoreductive surgery, primary tumor grade,
and stage
The survival of patients with primary cytoreduction in-
cluding liver resection was significantly higher compared
with those of patients with secondary cytoreductive sur-
gery including liver resection (15.63 versus 6.63 months,
log-rank p = 0.057, 90 % CI) (Fig. 1). Survival of patients
undergoing liver resection as part of primary cytoreduc-
tion was not statistically significant compared to the pa-
tients with liver resection as part of all other non-primaryrgery versus liver resections as part of secondary cytoreduction
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quaternary (log-rank p = 0.154)). Stage of the primary
tumor was not significantly associated with survival; pa-
tients with primary tumor stages I–II had better median
survival than those with stages III–IV, but the differ-
ence is not statistically significant (20.13 versus 12.35,
log-rank p = 0.462). Survival was not significantly better
for patients with G1–G2 grade of the primary tumor
compared to G3 grade (0 = 0.092).
Discussion
The important role of surgery in the treatment of ovar-
ian cancer has been first advocated by Meigs [19], al-
most 100 years ago, later objectified by the landmark
papers of Griffiths in 1970 [3]; currently, the inverse re-
lationship between residual time following cytoreduction
and survival is an undisputed fact [2]. Since the liver is
either involved from the beginning or presents meta-
chronous metastases following primary cytoreduction
followed by adjuvant chemotherapy, a question may be
raised about a possible benefit of liver resection as part
of R0 cytoreduction either in a primary or subsequent
setting. Due to the development of the surgical tech-
nique and intraoperative and postoperative intensive
care, liver resection is becoming an increasingly safer
procedure [20]; however, due to the success of hepatec-
tomies for colorectal and neuroendocrine liver metasta-
ses, the role of liver resection for metastases originating
from other primaries has increasingly been questioned.
Liver resection for metastases originating from gyne-
cologic malignancies appears to be an extremely safeFig. 2 Survival following hepatectomy for liver metastases from peritoneal
origin. Hematogeneous hematogenous liver metastases, Peritoneal liver metprocedure since published papers on the subject report
0 mortality with morbidity rates ranging up to 37 % 8–
17, which is impressive given the fact that in all studies,
liver resection is accompanied by other significant
debulking procedures in the upper and lower abdomen.
Liver resection seems to bring survival benefit for pa-
tients with ovarian cancer liver metastases; Kamel et al.
matched the patients who underwent liver surgery to
patients similar in liver tumoral burden who underwent
biopsy only, obtaining a clear difference with statistical
significance of 53 versus 21 months median overall sur-
vival from time to diagnosis of liver metastases [9].
There also seems to be a clear survival difference fol-
lowing hepatectomy regarding the mechanism of liver
involvement (hematogenous versus peritoneal seeding)
[9]; however, liver resection for patients with trans-
glissonian involvement of the liver appears so effective
that it brings survival close to the ones with IIIC stage
ovarian cancer [12]. In the present study, an improved
rate of survival for patients with peritoneal liver metas-
tases was seen at the moment of primary, secondary,
tertiary, and quaternary cytoreductions; however, these
differences did not achieve statistical significance. The
median survival of patients with hepatectomy for liver
metastases from peritoneal seeding (n = 12) was higher
than that of patients with hepatectomy for liver metas-
tases from hematogenous origin (n = 19) (16.08 versus
12.66 months, log-rank p = 0.523) (Fig. 2). At primary
cytoreduction, we noticed a difference of survival
following hepatectomy regarding the mechanisms of
liver involvement: 34.33 months survival followingseeding versus hepatectomy for liver metastases from hematogenous
astases originating from peritoneal seeding
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peritoneal seeding versus 15.63 months survival for
the ones with hematogenous origin (log-rank p =
0.702). However, three patients with hepatectomy as
part of primary cytoreductive surgery were alive at
139, 128, and 122 months of follow-up. A difference of
survival regarding the mechanisms of involvement is
maintained in the setting of secondary cytoreduction
with an overall survival of 22 months for patients with
liver metastases of peritoneal origin versus 10 months
for the ones with hematogenous origin. Interestingly,
patients submitted to hepatectomy during tertiary
cytoreduction obtained impressive survival, with me-
dian survival of 62.86 months (range, 1–128).
In a study on 27 patients with liver resection at the
time of secondary cytoreduction, Kolev et al. showed
that the interval from the primary surgery (<24 months)
and optimal secondary cytoreduction was significantly
associated with the longest survival [10].
Liver resection remains safe with 0 mortality and a
25 % morbidity but with most complications solved in a
conservatory manner.
Conclusions
Liver resection for advanced ovarian cancer is a safe pro-
cedure for primary up to quaternary cytoreduction and
may bring survival benefit. There is a difference in prog-
nosis following hepatectomy between patients with liver
metastases via hematogenous spread and the ones with
liver involvement via peritoneal contamination in favor
of the latter category.
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